||Removes all types of DOACs including dabigatran, apixaban, rivaroxaban and edoxaban, with minimal effect on currently-known clotting variables.
ARTG listed in Australia, CE marked in Europe
DOAC-Stop™ removes all types of Direct Oral Anti-Coagulants (DOACs; dabigatran, apixaban, rivaroxaban, and edoxaban, etc) from test plasmas with minimal effect on underlying blood clotting tests. Just add one mini-tablet per 1ml test plasma (volume is not critical), mix for 10 minutes and centrifuge down the adsorbent. The resulting plasma is then depleted of DOACs and yields similar APTT, dRVVT , PT(INR) and other results as if DOACs had not been present.
Reversing agents coming into therapeutic use for individual DOACs are not widely available for lab tests. DOAC-Stop™ is now offered for simplifying the diagnostic problems associated with DOACs. It absorbs up to an estimated 2,000ng/ml of any DOAC in less than 10 minutes. Unlike therapeutic additives for reversing DOACs it leaves no residual effect. It can be used for checking if DOACs are present in samples giving unexpectedly prolonged clotting test or abnormal chromogenic test results. There is negligible interference with vitamin K antagonist or heparinoid anticoagulants. Plasmas treated with DOAC-Stop™ can be used for valid factor assays and in testing for thrombotic risk. In particular it can prevent false LAC positive results due to DOACs or other agents in testing for lupus anticoagulants.
Recent papers on DOAC-Stop™ published in peer-reviewed journals:
1. Exner T, et al. "The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays". International Journal Laboratory Hematology 2020;00:1–8.
2. Favaloro E, et al. "Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa". Thrombosis Research 180 (2019) 10–19
3. Slavic L, et al. "Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban". Clinical and Applied Thrombosis/Hemostasis. 2019; Volume 25: 1-6
4. Zabczyk M, et al. "The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venouse thromboembolism patients receiving direct oral anticoagulants". De Gruyter Clin Chem Lab Med 2019;
5. Exner T, et al. "Effect of an activated charcoal product (DOAC Stop™) intended for extracting DOACs on various other APTT-prolonging agents". Clin Chem Lab Med. 2019; 57: 690-696.
6. Exner T, et al. "Clotting test results correlate better with DOAC concentrations when expressed as a "Correction Ratio"; results before/after extraction with the DOAC Stop reagent". Thromb Res 2019; 179: 69-72
7. Favresse J, et al. "Evaluation of the DOAC Stop procedure to overcome the effect of DOACs on several thrombophilia screening tests". TH Open, 2018; 2: e202-e209.
8. Jacquemin M, et al. "The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays". Int. J. Lab. Haematol. 2018; 40: 442-447.
9. Kopatz WF, et al. "Use of DOAC Stop for elimination of anticoagulants in thrombin generation assays". Thromb. Res. 2018; 170: 97-101.
10. Platton S, Hunt C. "Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban". Int J Lab Haematol. 2018; 1-7.
11. Exner T, et al. "Simple method for removing DOACs from plasma samples" Thromb. Res. 2018; 163: 117-122.